119 filings
Page 5 of 6
8-K
7elz7afh5mldeum
7 Aug 18
Cara Therapeutics Reports Second Quarter 2018 Financial Results
4:11pm
8-K
nv7vtsbmwk850
6 Aug 18
Departure of Directors or Certain Officers
4:10pm
8-K
na325u ond4f20
23 Jul 18
Cara Therapeutics Announces Pricing of $85.5 Million Offering of Common Stock
4:10pm
8-K
tu70p82bt3apuxw
17 Jul 18
Cara Therapeutics Announces Proposed Offering of Common Stock
5:24pm
8-K
hs8b8
27 Jun 18
Cara Therapeutics Reports PositiveTop-Line Data from Adaptive Phase 2/3 Trial of I.V. CR845 in Patients Undergoing Abdominal Surgery
4:06pm
8-K
2e2kxxsia76
8 Jun 18
Submission of Matters to a Vote of Security Holders
4:04pm
8-K
3bqfuydb71iu806e7e
23 May 18
Cara receives upfront payment of $50 million in cash and an equity investment of $20 million
8:30am
8-K
4k7hb
23 May 18
Entry into a Material Definitive Agreement
6:06am
8-K
a3osult0
9 May 18
Cara Therapeutics Reports First Quarter 2018 Financial Results
4:10pm
8-K
nar s1k0wa2xk
15 Mar 18
Cara Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
12:00am
8-K
bxzolmidw
12 Mar 18
Departure of Directors or Certain Officers
12:00am
8-K
4f2eelgfn2c
2 Nov 17
Cara Therapeutics Reports Third Quarter 2017 Financial Results
12:00am
8-K
mrvc9ok1617jcshqv
4 Aug 17
Departure of Directors or Certain Officers
12:00am
8-K
zg0teu69bxg7l2dd
3 Aug 17
Cara Therapeutics Reports Second Quarter 2017 Financial Results
12:00am
8-K
zgv 9g9ih2l1
22 Jun 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
sqrwtf
4 May 17
Cara Therapeutics Reports First Quarter 2017 Financial Results
12:00am
8-K
obzs7gzyql6p1
3 Apr 17
Cara Therapeutics Announces Proposed Offering of Common Stock
12:00am
8-K
5qxdoths
28 Mar 17
Cara Therapeutics Announces PositiveTop-Line Data
12:00am
8-K
jnk3iruibp qs6o3cba
9 Mar 17
Cara Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results
12:00am
8-K
wuvprfg77 w9pd
3 Nov 16
Cara Therapeutics Reports Third Quarter 2016 Financial Results
12:00am